Percutaneous Removal and Margin Ablation for Breast Cancer
Completed · Phase 1/Phase 2
Conditions studied: Breast Cancer
In brief
We hypothesize that radiofrequency ablation after single-insertion image guided vacuum assisted biopsy (IVEB) can be used to achieve negative margins in small unicentric breast cancers (≤1.5 cm).
Key facts
- Study ID
- NCT00574301
- Run by
- University of Arkansas
- People needed
- 32
- Starts
- 2002-03-01
- Expected to finish
- 2011-10-01
- Last updated by the study team
- 2013-07-25
Who can join
Age: 18 and older, up to 90. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- Female, 18 to 90 years of age
- Non-pregnant, not breastfeeding
- Pre-study documentation of:
- Size ≤1.5 cm cancer successfully removed by US-guided IVEB within 30 days of registration
- Uni-centricity, unilateral cancer by radiology (mammogram and MRI)
- Location of abnormality > 1 cm from the skin
- Ductal Carcinoma, Invasive (Grade I-III) or In-Situ
- No palpable axillary or supraclavicular lymph nodes
- Good general health
- Zubrod Performance Status of 0, 1, or 2
- If prior non-breast malignancy, must have 5 year disease-free survival
- No prior chemotherapy
- Hormonal therapy must be stopped
- Therapy with tamoxifen must have been of 14 days or less duration
You may not qualify if…
- Subjects less than 18 years of age or greater than 90 years of age
- Pregnant or breastfeeding
- Male
- Prior Breast Biopsy affected breast
- Breast implants
- Multicentric disease, bilateral disease
- Residual disease after IVEB of > 1cm on MRI
- Lesions > 1.5 cm in diameter
- Lesions < 1 cm from skin surface
- Previous radiation therapy to the breast
Where it is running
- University of Arkansas For Medical Sciences — Little Rock, Arkansas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.